Lisa Delfini is CFO at Trevi Therapeutics, Inc. (TRVI). They have made 1 open-market trade across 1 company since 2023, most recently 2025-01-08.
CIK 0001873253
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TRVI | 59,660 | $835K |
Shares reported on the most recent Form 4, priced at the 2025-01-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TRVI | SELL | 2024-05-22 | 2024-05-24 | $2.64 | $11K | -2.0% | +4.8% | +9.5% |
| TRVI | SELL · 10b5-1 | 2023-10-11 | 2023-10-12 | $2.02 | $2K | -9.5% | -32.7% | -33.2% |
| TRVI | SELL · 10b5-1 | 2023-09-11 | 2023-09-13 | $2.20 | $2K | -2.3% | -8.1% | -43.4% |
| TRVI | SELL · 10b5-1 | 2023-08-11 | 2023-08-14 | $2.36 | $2K | -3.8% | -9.6% | -43.9% |
| TRVI | SELL · 10b5-1 | 2023-07-11 | 2023-07-12 | $2.34 | $2K | +3.1% | +5.8% | -9.8% |
| TRVI | SELL · 10b5-1 | 2023-06-12 | 2023-06-14 | $2.64 | $2K | -23.0% | -16.4% | -15.5% |
| TRVI | SELL · 10b5-1 | 2023-05-11 | 2023-05-15 | $2.89 | $2K | -5.0% | -1.9% | -8.1% |
| TRVI | SELL · 10b5-1 | 2023-04-11 | 2023-04-12 | $1.84 | $2K | +51.4% | +54.6% | +24.0% |
| TRVI | SELL · 10b5-1 | 2023-03-13 | 2023-03-15 | $1.75 | $2K | +4.6% | +8.6% | +50.6% |
| TRVI | SELL · 10b5-1 | 2023-02-13 | 2023-02-15 | $2.45 | $21K | -6.6% | -30.1% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.